NeuroDerm Ltd. (NDRM) Rating Lowered to Hold at Zacks Investment Research
NeuroDerm Ltd. (NASDAQ:NDRM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday.
According to Zacks, “Neuroderm Ltd. is a clinical-stage pharmaceutical company. It is developing next-generation treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson’s disease (PD). Its product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. NeuroDerm Ltd. is headquartered in Rehovot, Israel. “
Separately, Jefferies Group raised their price objective on NeuroDerm from $28.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, September 6th.
Shares of NeuroDerm (NASDAQ:NDRM) opened at 19.80 on Friday. The company’s market cap is $429.74 million. The stock’s 50 day moving average price is $18.21 and its 200-day moving average price is $17.50. NeuroDerm has a 52 week low of $11.76 and a 52 week high of $20.52.
NeuroDerm (NASDAQ:NDRM) last issued its quarterly earnings data on Thursday, August 25th. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.32). Analysts expect that NeuroDerm will post ($1.47) EPS for the current year.
A number of large investors have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new stake in shares of NeuroDerm during the second quarter worth $246,000. Scopia Capital Management LP increased its stake in shares of NeuroDerm by 23.1% in the first quarter. Scopia Capital Management LP now owns 3,383,359 shares of the company’s stock worth $47,773,000 after buying an additional 634,321 shares during the last quarter. Opaleye Management Inc. acquired a new stake in shares of NeuroDerm during the first quarter worth $544,000. Swiss National Bank increased its stake in shares of NeuroDerm by 50.0% in the second quarter. Swiss National Bank now owns 22,800 shares of the company’s stock worth $371,000 after buying an additional 7,600 shares during the last quarter. Finally, Alps Advisors Inc. increased its stake in shares of NeuroDerm by 25.6% in the second quarter. Alps Advisors Inc. now owns 30,412 shares of the company’s stock worth $494,000 after buying an additional 6,192 shares during the last quarter. Institutional investors and hedge funds own 42.93% of the company’s stock.
NeuroDerm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa/carbidopa (LD/CD) or apomorphine concentrations and dosages.
Receive News & Stock Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related stocks with our FREE daily email newsletter.